See more : NN, Inc. (NNBR) Income Statement Analysis – Financial Results
Complete financial analysis of Medigen Biotechnology Corp. (3176.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medigen Biotechnology Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Sydinvest Konservativ (SYVKUA.CO) Income Statement Analysis – Financial Results
- Pro-Ship Incorporated (PSHPF) Income Statement Analysis – Financial Results
- Adara Acquisition Corp. (ADRA-UN) Income Statement Analysis – Financial Results
- Arverne Group (ARVEN.PA) Income Statement Analysis – Financial Results
- American National Group, Inc. (ANAT) Income Statement Analysis – Financial Results
Medigen Biotechnology Corp. (3176.TWO)
About Medigen Biotechnology Corp.
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 1.16B | 1.06B | 3.92B | 614.18M | 552.35M | 407.31M | 427.48M | 399.89M |
Cost of Revenue | 540.39M | 982.88M | 1.39B | 385.94M | 331.20M | 327.61M | 339.56M | 345.73M |
Gross Profit | 617.33M | 73.07M | 2.53B | 228.24M | 221.15M | 79.70M | 87.91M | 54.17M |
Gross Profit Ratio | 53.32% | 6.92% | 64.59% | 37.16% | 40.04% | 19.57% | 20.57% | 13.55% |
Research & Development | 1.34B | 1.32B | 1.38B | 803.37M | 664.24M | 551.87M | 450.42M | 431.23M |
General & Administrative | 247.72M | 241.55M | 283.35M | 245.42M | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 251.92M | 160.75M | 93.26M | 95.88M | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 499.64M | 421.34M | 369.21M | 337.03M | 319.23M | 290.24M | 284.01M | 373.27M |
Other Expenses | 0.00 | 87.15M | 461.94M | 114.99M | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 1.85B | 1.74B | 1.75B | 1.14B | 983.47M | 842.11M | 734.43M | 804.50M |
Cost & Expenses | 2.39B | 2.72B | 3.13B | 1.53B | 1.31B | 1.17B | 1.07B | 1.15B |
Interest Income | 89.07M | 8.88M | 3.16M | 2.27M | 7.39M | 4.15M | 31.46M | 15.71M |
Interest Expense | 55.86M | 39.45M | 19.07M | 31.88M | 31.60M | 23.12M | 19.20M | 10.86M |
Depreciation & Amortization | 178.38M | 191.65M | 198.43M | 218.84M | 213.45M | 211.87M | 216.90M | 159.15M |
EBITDA | -1.04B | -1.48B | 1.45B | -574.71M | -567.34M | -549.48M | -470.13M | -763.50M |
EBITDA Ratio | -90.23% | -139.72% | 25.17% | -112.89% | -99.37% | -135.17% | -100.50% | -147.83% |
Operating Income | -1.23B | -1.67B | 789.20M | -912.17M | -762.33M | -762.42M | -646.52M | -750.33M |
Operating Income Ratio | -106.51% | -157.87% | 20.12% | -148.52% | -138.02% | -187.19% | -151.24% | -187.63% |
Total Other Income/Expenses | -45.77M | -205.64M | 347.23M | 32.17M | -55.45M | -22.05M | -59.39M | -183.17M |
Income Before Tax | -1.28B | -1.61B | 1.24B | -825.44M | -759.54M | -784.47M | -705.95M | -933.51M |
Income Before Tax Ratio | -110.46% | -152.51% | 31.48% | -134.40% | -137.51% | -192.60% | -165.14% | -233.44% |
Income Tax Expense | 191.21M | 58.87M | 65.73M | -32.63M | 8.72M | 16.00M | -480.00K | -40.87M |
Net Income | -561.30M | -675.87M | -52.61M | -337.92M | -255.72M | -442.67M | -466.75M | -568.31M |
Net Income Ratio | -48.48% | -64.01% | -1.34% | -55.02% | -46.30% | -108.68% | -109.19% | -142.12% |
EPS | -4.03 | -4.86 | -0.38 | -2.43 | -1.84 | -3.19 | -3.37 | -4.10 |
EPS Diluted | -4.03 | -4.86 | -0.38 | -2.43 | -1.84 | -3.19 | -3.37 | -4.10 |
Weighted Avg Shares Out | 139.35M | 139.13M | 138.97M | 138.99M | 138.69M | 138.69M | 138.69M | 138.69M |
Weighted Avg Shares Out (Dil) | 139.35M | 139.13M | 138.97M | 138.99M | 138.69M | 138.69M | 138.69M | 138.69M |
Source: https://incomestatements.info
Category: Stock Reports